Lapatinib is an anti-cancer medication classified as a kinase inhibitor, primarily used to treat HER2-positive breast cancer. It is often administered in combination with other therapies for advanced or metastatic cases. Lapatinib works by inhibiting the activity of the HER2 protein, which is overexpressed in some breast cancers, thus slowing down cancer cell growth and promoting apoptosis. In summary, it helps in the targeted treatment of specific breast cancer types.
Lapatinib inhibits the tyrosine kinase activity of the HER2 receptor, blocking downstream signaling pathways that promote cancer cell proliferation and survival.


